Stock Financial Ratios, Dividends, Split History

TMHC / Taylor Morrison Home Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,441.55
Enterprise Value ($M)3,365.68
Book Value / Share14.35
Price / Book1.55
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 62,061,000
Common Stock Shares Outstanding 119,579,612
Weighted Average Number Of Diluted Shares Outstanding 120,915,000
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 111,232,162
Weighted Average Number Of Shares Outstanding Conversion Of Principal Equityholders Noncontrolling Interest 57,556,000
Common Shares Outstanding2 883,921
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.04
Return on Equity (ROE)0.32
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenue Other Financial Services69,136,000.00
Home Building Revenue3,799,061,000.00
Real Estate Revenue Net3,885,290,000.00
Net Income176.65
Earnings Per Share Diluted1.47
Earnings Per Share Basic1.47
Cash Flow Statement (mra) ($M)
Cash From Operations386.23
Cash from Investing-35.99
Cash from Financing-35.99
Identifiers and Descriptors
Central Index Key (CIK)1562476
Related CUSIPS
87724P956 87724P906

Split History

Stock splits are used by Taylor Morrison Home Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

BRIEF-Taylor Morrison Home's CEO Sheryl Palmer's Total 2017 Compensation Was $6.2 Mln Vs $6 Mln In 2016

2018-04-17 reuters

Top Ranked Value Stocks to Buy for February 9th

2018-02-09 zacks
Here are four stocks with buy rank and strong value characteristics for investors to consider today, February 9th: (18-0)

New Strong Buy Stocks for February 8th

2018-02-08 zacks
Foot Locker, Inc. (FL - Free Report) : This athletic shoes and apparel retailer has seen the Zacks Consensus Estimate for its current year earnings increasing 0.5% over the last 60 days. (28-1)

How Far Will Economic & Wage Growth Push Housing Demand?

2018-02-07 zacks
Housing is on solid ground. While the newly enacted tax reform bill creates a complicated set of impact, the underlying trends for the U.S. homebuilding industry are positive, given solid macroeconomic fundamentals and tight existing home inventory. Importantly, disruptions caused by the hurricanes and other natural disasters also seem to have short lived as revealed by recent economic data reports. (48-0)

Taylor Morrison's (TMHC) CEO Sheryl Palmer on Q4 2017 Results - Earnings Call Transcript

2018-02-07 seekingalpha
At this time, all participants are in a listen-only mode. Later we'll conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference call is being recorded. (35-0)

CUSIP: 87724P106